The Evolving IgA Nephropathy Landscape: Translating New Evidence and Updated Guidelines Into Managed Care Access Strategies

Program Description:

IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide and a leading contributor to progressive loss of kidney function, with an estimated 25% to 30% of patients developing kidney failure within 20 to 25 years. Because IgAN often occurs in early adulthood, its burden of dialysis, kidney transplantation, diminished quality of life, and substantial health care costs can accumulate over decades. The IgAN treatment landscape has shifted with updates to the 2025 Kidney Disease: Improving Global Outcomes guidelines, which call for more stringent proteinuria targets, and a growing roster of approved and late-stage investigational agents that address the underlying disease process rather than supportive care alone. For managed care pharmacists, Pharmacy and Therapeutics committee members, and other formulary decision makers, keeping pace with this evidence is essential to build coverage policies and utilization management strategies that support timely, appropriate access to therapy. This webinar connects IgAN pathophysiology and clinical evidence to real-world formulary and coverage decisions. Expert faculty will translate the latest guideline recommendations and clinical trial data into practical utilization management considerations while exploring managed care frameworks for formulary evaluation and patient access.

Target audience: Managed care pharmacists
Type of activity: Application
Release date: November 19, 2026
Expiration date: January 18, 2026
Time to complete activity: 1.0 hour
Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Apply immunoglobulin A nephropathy (IgAN) pathophysiology, clinical burden, and key predictors of disease progression to patient management strategies
• Use updated KDIGO guideline recommendations and emerging clinical trial evidence to guide treatment decision-making for patients with IgAN
• Investigate approved and late-stage investigational therapies for IgAN based on mechanism of action, efficacy, safety profiles, and anticipated impact on disease progression
• Employ managed care frameworks for formulary evaluation, coverage policy development, and utilization management to support timely patient access and optimal outcomes for individuals living with IgAN

Accreditation Information

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application-based activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number UAN: 0290-0000-26-321-L01-P. The activity is available for CE credit through January 18, 2027.

Obtaining Credit

All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Ami Gopalan, PharmD, MBA, FAMCP, has the following relevant financial relationships with ineligible companies to disclose:

Other Support: Otsuka

Employee: Precision AQ

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Sarah Viruet; and Brianna Winters have no financial relationships with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

At least 1 anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms